The Department of Vector Biology maintains a broad research portfolio, encompassing functional genomics, behaviour, and ecology of disease vectors, clinical trials, implementation research, and the development of tools for monitoring and evaluating of disease transmission. Our overarching aim is to contribute to the control and elimination of vector-borne diseases that disproportionately affect the world’s poorest populations. 

We apply our expertise and resources to accelerate discovery and societal impact through world class research, focussed on the following themes:  

1. Resistance
   The evolution of resistance, initially focused on insecticides and increasingly encompassing antimicrobial resistance (AMR), remains a cornerstone of our research strengths. LSTM has world-leading capabilities in this field including genomic surveillance and novel resistance screening technologies.
2. Trials and Implementation
   Our staff have led or played pivotal roles in numerous major vector control tool (VCT) trials and host one of the leading groups of VCT trialists globally, supported by an equitable network of partners. Future planned growth include the trialling of genetically modified mosquitoes and/or mosquitoes with altered microbiomes.
3. Control of Emerging and Re-emerging Vector-borne Pathogens
   We continue invest in, grow and diversify our portfolio in this area, including viral and tick-borne pathogens, to ensure resilience against emerging threats. 
4. Anthropogenic Change
   In recognition of the intersection of extreme weather events and anthropogenic change as major drivers of vector-borne disease (VBD) transmission risk, we will focus future research and growth in this emergent health issue.